🤗

Happy holidays from the Cedars-Sinai heart failure and transplant fellows! 🎄🤶🎉

Please join is tomorrow for the first in a series of free, monthly webinars focused on the care of patients with advanced HF. Episode #1: 🔘Contemporary Outcomes of LVADs, INTERMACS update, Dr. Kevin Koomalsingh 🔘Contemporary Outcomes of Heart Transplant, Dr. Jill Gelow

So proud to be part of a #HeartFailure Cardiology team that is at least 50% female Providence Oregon Jenna Kay Vidang Nguyen @GelowJill Women As One and also with an amazing group of 🌟Comrades Jacob Abraham, MD Daniel E. Westerdahl Josh Remick

How Howard White Got A Second Heart | Content by Providence youtu.be/d18smabWwhc via YouTube I am honored to know “H” and be part of the team that gave him a new birthday. Nike Providence Oregon CNN

A great start to the session on cardiogenic shock! SCAI validation study shows significant heterogeneity in SCAI shock stages depending on population and study. #TCT2021

Some key takeaways from the SCAI shock classification update. 1) Cardiac arrest modifier only relevant with the presence of coma 2) Gradations added within each stage with ongoing assessment of modifiers #TCT2021

One of the updates from the CSRC working groups earlier today. I’m excited about the potential of this registry and think it will add to excellent work currently done in the field. #TCT2021

Cardiogenic shock due to severe aortic stenosis can be a clinical challenge. Our interdisciplinary approach Providence Oregon using MCS as bridge to #TAVR is highlighted in this case series now out in JHLT. DOI:doi.org/10.1016/j.heal… How do you approach this scenario?

Invasive hemodynamics via PA catheter assessment are essential in risk stratifying PAH and CS. Fantastic talk by @SophiaAirhart Providence Oregon #ISHLT2022 #CSWG

In addition to mentorship, the truest form of support has been sponsorship from Jacob Abraham, MD. This distinction makes a real ally #womenasone Providence Oregon

Dr. Berman presenting the first year national UK DCD experience. DCD use on the rise. Although 30-day mortality equivalent, there were high rates of post-tx MCS with DCD (ECMO in their experience). Looking forward to reading full report #ISHLT2022

One of my favorite sessions chaired by Kiran Khush and @SophiaAirhart Providence Oregon on the use of cell-free DNA in as a compliment (and maybe one day replacement?) to biopsies in heart tx. Excited to see eventual outcomes from DETECT #ISHLT2022

👏👏👏

I always learn so much from Kate Kearney! Great perspectives shared at #ESCCongress on the Heart Team effort in cardiogenic shock ❤️‍🩹